Overview

RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY

Status:
Recruiting

Trial end date:
2022-08-30

Target enrollment:
0

Participant gender:
All

Summary

This is a randomized, placebo-controlled trial of RT001 in patients with PSP.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Retrotope, Inc.

Criteria

Inclusion Criteria:

1. Sign the informed consent form prior to entry into the study

2. Male or female subject with age 40 years to 80 years at the time of signed consent

3. Meets the MDS-PSP study group criteria for possible or probable progressive
supranuclear palsy with Richardson syndrome (postural instability and falls with
vertical ocular motor dysfunction)

4. Presence of PSP symptoms for less than 4 years

5. Score of <40 on the PSPRS-28

6. Ambulatory patients (with or without assistive device - no handheld help) and capable
of performing study assessments/evaluations

7. Subject has an identified, reliable, study partner (e.g., caregiver, family member,
social worker, or friend) who can assist in assuring that the subject is able to
travel to the required visits.

8. Willing to provide the necessary blood samples

Exclusion Criteria:

1. Received treatment with other experimental therapies within the last 30 days prior to
the first dose. The last dose of the prior experimental agent must have occurred more
than 5 half-lives prior to enrollment in the current trial.

2. Previously received treatment with RT001

3. Refusal to discontinue fish oils or other oil-based supplements for the duration of
the study (Screening/Baseline till last study procedure completed)

4. Mini mental state examination (MMSE) score less than 20 at screening

5. Subject resides at a skilled nursing or dementia care facility, or admission to such a
facility is planned during the study period

6. Evidence of any clinically significant neurological disorder other than PSP in
particular CBS

7. Evidence of a clear and robust benefit from levodopa at the time of screening.
Participants are permitted to take levodopa and other Parkinson's medications if the
dose had been stable for 60 days prior to screening

8. The subject has a history of or currently has schizophrenia, schizoaffective disorder
or bipolar disorder according to DSM-V or ICD-10 criteria

9. Subject has had a significant illness or infection requiring medical intervention in
the past 30 days

10. Subject has evidence of any disease or condition (based on either history, physical or
laboratory values) that might interfere with the conduct of the study

11. Is currently receiving active deep brain stimulation (DBS) that cannot be turned off

12. Any condition with a life expectancy of less than 2 years

13. Female who is breastfeeding or has a positive pregnancy test

14. Male participant or female participant of childbearing potential, who is sexually
active and unwilling/unable to use a highly effective birth control method throughout
the study

15. Unwilling or unable to comply with the requirements of this protocol, including the
presence of any condition (physical, mental, or social) that is likely to affect the
subject's ability to return for visits as scheduled

16. History, within the last 2 years, of alcohol abuse or physical opioid dependence